SSY Group Wins China Approval for Furosemide Bulk Drug

The latest update is out from SSY Group ( (HK:2005) ).

SSY Group Limited has secured approval from China’s National Medical Products Administration for its Furosemide as a bulk drug, enabling its use in the manufacture of preparations already on the market. This follows earlier regulatory approvals for Furosemide tablets and injections, underscoring the group’s expansion in key therapeutic segments.

Furosemide is indicated for conditions including edema, hypertension, electrolyte imbalances, Syndrome of Inappropriate Antidiuretic Hormone Secretion and prevention of acute kidney failure, placing SSY’s product within a widely used class of diuretics. The latest authorization strengthens SSY’s product portfolio in China’s hospital and prescription drug markets and signals continued progress in its pharmaceutical development pipeline for shareholders and potential investors.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company listed in Hong Kong, operating through subsidiaries to develop and manufacture drug products for the Chinese market. The group focuses on prescription medicines, including tablets, injections and bulk drug substances, targeting treatments in areas such as cardiovascular, renal and other systemic conditions.

Average Trading Volume: 9,035,207

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.41B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.